Does Rallies show Form 4 insider transactions for SINT?

Yes. Rallies tracks SINT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SINT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SINT. It does not provide personalized investment advice.

SINT (SiNtx Technologies, Inc. Common Stock) Stock Analysis - Insider Trades

SiNtx Technologies, Inc. Common Stock (SINT) is a publicly traded Healthcare sector company. As of May 21, 2026, SINT trades at $2.20 with a market cap of $9.19M and a P/E ratio of -0.43. SINT moved +0.00% today. Year to date, SINT is -40.11%; over the trailing twelve months it is -26.82%. Its 52-week range spans $1.71 to $8.60. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces SINT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SINT stock inside the company?

Recent SINT insider activity includes Lyons Christopher Michael bought 7.53K, Lyons Christopher Michael bought 758, MOYES JAY M bought 1.00K, Anderson Mark Lewis bought 3.00K, and Honigblum Gregg R. bought 3.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SINT Key Metrics

Key financial metrics for SINT
Metric	Value
Price	$2.20
Market Cap	$9.19M
P/E Ratio	-0.43
EPS	$-5.06
Dividend Yield	0.00%
52-Week High	$8.60
52-Week Low	$1.71
Volume	3.88K
Avg Volume	0
Revenue (TTM)	$1.03M
Net Income	$-10.89M
Gross Margin	46.84%

Recent SINT Insider Trades

Lyons Christopher Michael bought 7.53K (~$21.85K) on Mar 2, 2026.
Lyons Christopher Michael bought 758 (~$2.24K) on Feb 25, 2026.
MOYES JAY M bought 1.00K (~$2.91K) on Feb 23, 2026.
Anderson Mark Lewis bought 3.00K (~$9.06K) on Feb 18, 2026.
Honigblum Gregg R. bought 3.20K (~$13.70K) on Dec 8, 2025.

Latest SINT News

SINTX Technologies Completes First Human Implant and Secures $10M for Commercial Rollout — Mar 23, 2026
SINTX Technologies Completes First Human Surgery with FDA-Cleared SINAPTIC Foot & Ankle Implant — Mar 19, 2026

SINT Analyst Consensus

2 analysts cover SINT: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.

Common questions about SINT

Who is trading SINT stock inside the company?: Recent SINT insider activity includes Lyons Christopher Michael bought 7.53K, Lyons Christopher Michael bought 758, MOYES JAY M bought 1.00K, Anderson Mark Lewis bought 3.00K, and Honigblum Gregg R. bought 3.20K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SINT?: Yes. Rallies tracks SINT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SINT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SINT. It does not provide personalized investment advice.